Meta-analysis of short-acting insulin analogues in adult patients with type 1 diabetes: Continuous subcutaneous insulin infusion versus injection therapy

Diabetologia

Volumn 47, Issue 11, 2004, Pages 1895-1905

  Siebenhofer, A ^a   Plank, J ^a   Berghold, A ^a   Horvath, K ^a   Sawicki, P T ^b   Beck, P ^c   Pieber, T R ^a,c  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b St Franziskus Hospital Koln   (Germany)

^c JOANNEUM RESEARCH   (Austria)

Author keywords

Complications; Continuous subcutaneous insulin infusion; Diabetes mellitus; Hypoglycaemia; Intensified insulin therapy; Meta analysis; Radomised controlled trial

Indexed keywords

ASPART; HEMOGLOBIN A1C; INSULIN DERIVATIVE; INSULIN LISPRO; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CORRELATION ANALYSIS; DIABETES CONTROL; DISEASE COURSE; DRUG EFFECT; FREQUENCY ANALYSIS; HEMOGLOBIN DETERMINATION; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; INTERMETHOD COMPARISON; META ANALYSIS; PRIORITY JOURNAL; STANDARDIZATION; STATISTICAL SIGNIFICANCE;

ADULT; DIABETES MELLITUS, TYPE 2; HUMANS; INJECTIONS, SUBCUTANEOUS; INSULIN; INSULIN INFUSION SYSTEMS; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN;

EID: 12144251395     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-004-1545-x     Document Type: Article

References (63)

1. Zinman B (1989) The physiological replacement of insulin. An elusive goal. N Engl J Med 321:363-370
2. Mosekilde E, Jensen KS, Binder C, Pramming S, Thorsteinsson B (1989) Modeling absorption kinetics of subcutaneous injected soluble insulin. J Pharmacokinet Biopharm 17:67-87
3. Howey DC, Bowsher RR, Brunelle RL, Woodworth JR (1994) [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin. Diabetes 43:396-402
4. Torlone E, Fanelli C, Rambotti AM et al. (1994) Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28), Pro(B29)] in IDDM. Diabetologia 37:713-720
5. Johansson UB, Adamson UCK, Lins PES, Wredling RAM (2000) Improved blood glucose variability, HbA1c Insuman Infusat and less insulin requirement in IDDM patients using insulin lispro in CSII. The Swedish Multicenter Lispro Insulin Study. Diabetes Metab 26:192-196
6. Renner R, Pfutzner A, Trautmann M, Harzer O, Sauter K, Landgraf R (1999) Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog-CSII Study Group. Diabetes Care 22:784-788
7. Raskin P, Holcombe JH, Tamborlane WV et al. (2001) A comparison of insulin lispro and buffered regular human insulin administered via continuous subcutaneous insulin infusion pump. J Diab Compl 15:295-300
8. Anderson JH, Brunelle RL, Koivisto VA, Trautmann ME, Vignati L, DiMarchi R (1997) Improved mealtime treatment of diabetes mellitus using an insulin analogue. Multicenter Insulin Lispro Study Group. Clin Therap 19:62-72
9. Garg SK, Carmain JA, Braddy KC et al. (1996) Pre-meal insulin analogue insulin lispro vs Humulin R insulin treatment in young subjects with Type 1 diabetes. Diabet Med 13:47-52
10. Holleman F, Schmitt H, Rottiers R, Rees A, Symanowski S, Anderson JH (1997) Reduced frequency of severe hypoglycemia and coma in well-controlled IDDM patients treated with insulin lispro. The Benelux-UK Insulin Lispro Study Group. Diabetes Care 20:1827-1832
11. Del Sindaco P, Ciofetta M, Lalli C et al. (1998) Use of the short-acting insulin analogue lispro in intensive treatment of Type 1 diabetes mellitus: importance of appropriate replacement of basal insulin and time-interval injection-meal. Diabet Med 15:592-600
12. Anderson JH, Brunelle RL, Koivisto VA et al. (1997) Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Multicenter Insulin Lispro Study Group. Diabetes 46:265-270
13. Pfutzner A, Kustner E, Forst T et al. (1996) Intensive insulin therapy with insulin lispro in patients with type 1 diabetes reduces the frequency of hypoglycemic episodes. Exp Clin Endocrinol Diabetes 104:25-30
14. Hedman CA, Orre-Pettersson AC, Lindstrom T, Arnquist HJ (2001) Treatment with insulin lispro changes the insulin profile but does not affect the plasma concentrations of IGF-I and IGFBP-1 in type 1 diabetes. Clin Endocrinol 55:107-112
15. Schmauss S, Konig A, Landgraf R (1998) Human insulin analogue [Lys(B28), Pro(B29)]: the ideal pump insulin? Diabel Med 15:247-249
16. Gale EA (2000) A randomized, controlled trial comparing insulin lispro with human soluble insulin in patients with Type 1 diabetes on intensified insulin therapy. The UK Trial Group. Diabet Med 17:209-214
17. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF (1999) Improving the quality of reports of meta-analysis of randomised controlled trials: the QUOROM statement. Lancet 354:1896-1900
18. The Cochrane Library (2003) Issue 4. Oxford: Update Software
19. Jadad AR, Moore RA, Carroll D et al. (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1-12
20. Schulz KF, Chalmers I, Hayes RJ, Altman DG (1995) Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 273:408-412
21. Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A (2002) Meta-analyses involving cross-over trials: methodological issues. Int J Epidemiol 31:140-149
22. Curtin F, Altman DG, Elbourne DR (2002) Meta-analysis combining parallel and cross-over clinical trials. I: continuous outcomes. Stat Med 21:2131-2144
23. Anderson JH Jr, Brunelle RL, Keohane P et al. (1997) Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Arch Int Med 157:1249-1255
24. Roach P, Yue L, Arora V (1999) Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation. Humalog Mix25 Study Group. Diabetes Care 22:1258-1261
25. Ross SA, Zinman B, Campos RV, Strack T (2001) A comparative study of insulin lispro and human regular insulin in patients with type 2 diabetes mellitus and secondary failure of oral hypoglycemic agents. Clin Invest Med 24:292-298
26. Herz M, Profozic V, Arora V et al. (2002) Effects of a fixed mixture of 25% insulin lispro and 75%NPL on plasma glucose during and after moderate physical exercise in patients with type 2 diabetes. Curr Med Res Opin 18:188-193
27. Herz M, Arora V, Campaigne BN, Scholtz HE, Potgieter MA, Mollentze W (2003) Humalog Mix 25 improves 24-hour profiles compared with the human insulin mixture 30/70 in patients with type 2 diabetes mellitus. S Afr Med J 93:219-223
28. Deeb LC, Holcombe JH, Brunelle R et al. (2001) Insulin lispro lowers postprandial glucose in prepubertal children with diabetes Pediatrics 108:1175-1179
29. Tupola S, Komulainen J, Jaaskelainen J, Sipila I (2001) Post-prandial insulin lispro vs. human regular insulin in prepubertal children with type 1 diabetes mellitus. Diabet Med 18:654-658
30. Ford-Adams ME, Murphy NP, Mooore EJ et al. (2003) Insulin lispro: a potential role in preventing nocturnal hypoglycaemia in young children with diabetes mellitus. Diabet Med 20:656-660
31. Holcombe JH, Zalani S, Arora VK, Mast CJ; Lispro in Adolescents Study Group (2002) Comparison of insulin lispro with regular human insulin for the treatment of type 1 diabetes in adolescents. Clin Ther 24:629-638
32. Jacobs MA, Keulen ET, Kanc K, Casteleijn S, Scheffer P, Deville W, Heine R (1997) Metabolic efficacy of preprandial administration of Lys(B28), Pro(B29) human insulin analog in IDDM patients: a comparison with human regular insulin during a three-meal test period. Diabetes Care 20:1279-1286
33. Persson B, Swahn ML, Hjertberg R et al. (2002) Insulin lispro therapy in pregnancies complicated by type 1 diabetes mellitus. Diabetes Res Clin Pract 58:115-121
34. Jovanovic L, Ilic S, Pettitt DJ et al. (1999) Metabolic and immunologic effects of insulin lispro in gestational diabetes. Diabetes Care 22:1422-1427
35. Mecacci F, Carignani L, Cioni R et al. (2003) Maternal metabolic control and perinatal outcome in women with gestational diabetes treated with regular or lispro insulin: comparison with non-diabetic pregnant women. Eur J Obstet Gynecol Reprod Biol 111:19-24
36. Kotsanos JG, Vignati L, Huster L et al. (1997) Health-related quality-of-life results from multinational clinical trials of insulin lispro. Diabetes Care 20:948-958
37. Bott U, Ebrahim S, Hirschberger S, Skovlund SE (2003) Effect of the rapid-acting insulin analogue insulin aspart on the quality of life treatment satisfaction in patients with Type 1 diabetes. Diabet Med 20:626-634
38. Bode BW, Strange P (2001) Efficacy, safety, and pump compatibility of insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes. Diabetes Care 24:69-72
39. Bode B, Weinstein R, Bell D et al. (2002) Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion. Diabetes Care 25:439-444
40. Zinman B, Tildesley H, Chiasson JL et al. (1997) Insulin lispro in CSII: results of a double-blind crossover study. Diabetes 46:440-443
41. Ferguson SC, Strachan MWJ, Janes JM, Frier BM (2001) Severe hypoglycaemia in patients with type 1 diabetes and impaired awareness of hypoglycaemia: a comparative study of insulin lispro and regular human insulin. Diabetes Metab Res Rev 17:285-291
42. Heller SR, Amniel SA, Mansell P (1999) Effect of the fast-acting insulin analog lispro on the risk of nocturnal hypoglycemia during intensified insulin therapy. UK Lispro Study Group. Diabetes Care 22:1607-1611
43. Home PD, Lindholm A, Hylleberg B, Round P (1998) Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. UK Insulin Aspart Study Group. Diabetes Care 21:1904-1909
44. Home PD, Lindholm A, Riis A (2000) European Insulin Study Group. Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial. Diabet Med 17:762-770
45. Iwamoto Y, Akanuma Y, Niimi H, Sasaki N, Tajima N, Kawamori R (2001) Comparison between insulin aspart and soluble human insulin in type 1 diabetes (IDDM) patients treated with basal-bolus insulin therapy - Phase III clinical trial in Japan. J Jpn Diabetes Soc 44:799-811
46. Provenzano C, Vero R, Oliva A et al. (2001) Lispro insulin in Type 1 diabetic patients on a Mediterranean or normal diet: a randomized, cross-over comparative study with regular insulin. Diabetes Nutr Metab 14:133-139
47. Ciofetta M, Lalli C, Del Sindaco P et al. (1999) Contribution of postprandial versus interprandial blood glucose to HbA1c in type 1 diabetes on physiologic intensive therapy with lispro insulin at mealtime. Diabetes Care 22:795-800
48. Annuzzi G, Del Prato S, Arcari R et al. (2001) Preprandial combination of lispro and NPH insulin improves overall blood glucose control in type 1 diabetic patients: a multicenter randomized crossover trial. Nutr Metab Cardiovasc Dis 11:168-175
49. Raskin P, Guthrie RA, Leiter L, Riis A, Jovanovic L (2000) Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care 23:583-588
50. Recasens M, Aguilera E, Morinigo R et al. (2003) Insulin lispro is as effective as regular insulin in optimising metabolic control and preserving beta-cell function at onset of type 1 diabetes mellitus. Diab Res Clin Pract 60:153-159
51. Roach P, Trautmann M, Arora V, Sun B, Anderson JH Jr, Haslbeck M (1999) Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin lispro-protamine formulations, insulin lispro Mix25 and insulin lispro Mix50. Mix50 Study group. Clin Ther 21:523-534
52. Vignati L, Anderson JH Jr, Iversen PW (1997) Efficacy of insulin lispro in combination with NPH human insulin twice per day in patients with insulin-dependent or non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group. Clin Ther 19:1408-1421
53. Boehm BO, Home PD, Behrend C, Kamp NM, Lindholm A (2002) Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in type 1 and type 2 diabetic patients. Diabet Med 19:393-399
54. Skrha J, Smahelova A, Andel M et al. (2002) Insulin lispro improves postprandial glucose control in patients with diabetes mellitus. Sb Lek 103:15-21
55. Plank J, Wutte A, Brunner G et al. (2002) A direct comparison of insulin aspart and insulin lispro in patients with type 1 diabetes. Diabetes Care 25:2053-2057
56. Homko C, Deluzio A, Jimenez C, Kolaczynski JW, Boden G (2003) Comparison of insulin aspart and lispro. Diabetes Care 26:2027-2031
57. The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986
58. Owens DR, Zinman B, Bolli GB (2001) Insulins today and beyond. Lancet 358:739-746
59. Pramming S, Thorsteinsson B, Bendtson I, Binder C (1990) The relationship between symptomatic and biochemical hypoglycemia in insulin-dependent diabetic patients. J Int Med 228:641-646
60. The DCCT Research Group (1991) Epidemiology of severe hypoglycemia in the Diabetes Control and Complications Trial. Am J Med 90:450-459
61. Windeler J, Lange S (1995) Events per person year - a dubious concept. BMJ 310:454-456
62. Mühlhauser I, Overmann H, Bender R, Bott U, Berger M (1998) Risk factors of severe hypoglycaemia in adult patients with Type 1 diabetes - a prospective population based study. Diabetologia 41:1274-1282
63. Cryer PE (2002) Hypoglycaemia the limiting factor in the glycaemic management of Type I and Type II diabetes. Diabetologia 45:937-948